Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148079 | 0.86 | TDP1 (0.50) | FFAR4SCN5ACYP2C9FFAR1GPR3 | |
| SCHEMBL6205088 | 0.82 | GPR3 (0.41) | FFAR4SCN5ACYP2C9FFAR1GPR3 | |
| SCHEMBL16959124 | 0.82 | FFAR4 (0.41) | FFAR4SCN5ACYP2C9FFAR1GPR3 | |
| SCHEMBL2824893 | 0.80 | GPR3 (0.42) | FFAR4SCN5ACYP2C9FFAR1GPR3 | |
| SCHEMBL6500895 | 0.80 | GPR3 (0.42) | SCN5ACYP2C9GPR3CES1CYP3A4 | |
| SCHEMBL29627452 | 0.79 | ERN1 (0.61) | GPR3ERN1EPHX2 | |
| SCHEMBL17822065 | 0.79 | GPR3 (0.41) | FFAR4SCN5ACYP2C9GPR3CES1 | |
| SCHEMBL6092323 | 0.79 | NPC1 (0.44) | FFAR4SCN5ACYP2C9GPR3CES1 | |
| SCHEMBL1211619 | 0.79 | ERN1 (0.61) | GPR3ERN1EPHX2 | |
| SCHEMBL26930964 | 0.79 | GAA (0.43) | SCN5ACYP2C9GPR3CES1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479844-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20210403476-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-12-30 | — | — | US | disclosed |
| US-20210403476-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-12-30 | — | — | US | disclosed |
| CN-113573713-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3856193-A1 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020069322-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-1551836-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031190-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-6555552-B2 | Psychological disorders; analgesics; antiinflammatory agents | MERCK SHARP & DOHME LTD. (GB) | 2003-04-29 | — | — | US | disclosed |
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403476-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | FFAR4 2492/4885SCN5A 5/4885CYP2C9 3258/4885 |
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | CXCR1, CXCR6, CCR6 | FFAR4 492/4885SCN5A 346/4885CYP2C9 1545/4885 |
| US-12479844-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | FFAR4 2492/4885SCN5A 5/4885CYP2C9 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.